HC Wainwright & Co. Maintains Buy on Processa Pharma, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Processa Pharma (NASDAQ:PCSA) but lowers the price target from $8 to $6.
August 19, 2024 | 11:15 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Processa Pharma but lowers the price target from $8 to $6.
The Buy rating suggests continued confidence in Processa Pharma's prospects, but the lowered price target indicates tempered expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100